Drugs with activity against Mycobacterium tuberculosis;Fármacos con actividad frente a Mycobacterium tuberculosis

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 6, 2003, Pages 299-308

  Coll, Pere ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Antituberculosis drugs; Resistance mechanisms; Tuberculosis treatment

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LINEZOLID; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ANEMIA; ANTIBACTERIAL ACTIVITY; BACTERIAL METABOLISM; BACTERIAL STRAIN; CHROMOSOME MUTATION; DEPRESSION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GENE LOCUS; HEPATITIS; HUMAN; HYPERURICEMIA; INFECTION CONTROL; LUNG TUBERCULOSIS; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHENOTYPE; POLYNEUROPATHY; PRURITUS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; URTICARIA; VESTIBULAR DISORDER; VISUAL ACUITY;

EID: 0037480742     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13048578     Document Type: Review

References (75)

1. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994;13:908-14.
2. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002;46:267-74.
3. Jarlier V, Nikaido H. Mycobacterial cell wall: Structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 1994;123:11-8.
4. Kwon HH, Tomioka H, Saito H. Distribution and characterization of beta-lactamases of mycobacteria and related organisms. Tuber Lung Dis 1995;76:141-8.
5. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
6. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397-406.
7. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Rubén F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359-74.
8. Bloom BR, Murray CJ. Tuberculosis: Commentary on a reemergent killer. Science 1992;257:1055-64.
9. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Jama 1999;282:677-86.
10. Haas DW, Des Prez RM. Tuberculosis and acquired immunodeficiency syndrome: A historical perspective on recent developments. Am J Med 1994;96:439-50.
11. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-9.
12. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001;2:164-8.
13. Telenti A. Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax 1998;53:793-7.
14. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.
15. Heym B, Honore N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs WR Jr, et al. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: A molecular study. Lancet 1994;344:293-8.
16. Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-11.
17. Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1238-44.
18. Salomon N, Perlman DC, Friedmann P, Buchstein S, Kreiswirth BN, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1245-52.
19. Torres MJ, Criado A, Palomares JC, Aznar J. Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J Clin Microbiol 2000;38:3194-9.
20. García de Viedma D, Del Sol Diaz Infantes M, Lasala F, Chaves F, Alcalá L, Bouza E. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol 2002;40:988-95.
21. Lipshutz RJ, Morris D, Chee M, Hubbell E, Kozal MJ, Shah N, et al. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 1995;19:442-7.
22. Piatek AS, Tyagi S, Pol AC, Telenti A, Miller LP, Kramer FR, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol 1998;16:359-63.
23. World Health Organisation. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Genève; WHO; 1997.
24. World Health Organisation. Antituberculous drug resistance in the world. Report no. 2- Prevalence and trends. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Genève: WHO, 2000.
25. Martin-Casabona N, Alcaide F, Coll P, González J, Manterola JM, Salvado M, et al. Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Med Clin (Barc) 2000;115:493-8.
26. Wilson TM, De Lisle GW, Collins DM. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 1995;15:1009-15.
27. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.
28. Rouse DA, DeVito JA, Li Z, Byer H, Morris SL. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: Effects on catalase-peroxidase activities and isoniazid resistance. Mol Microbiol 1996;22:583-92.
29. Middlebrook G. Isoniazid resistance and catalase activity of tubercle bacilli. Am Rev Tuberc 1954;69:471-2.
30. Vilcheze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, Sacchettini JC, et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 2000;182:4059-67.
31. Sacchettini JC, Blanchard JS. The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol 1996;147:36-43.
32. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.
33. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970;20:810-4.
34. Mensa J, Gatell J, Jimenez de Anta M, G P, Dominguez-Gil A. Guia terapéutica antimicrobiana. Barcelona: Masson, 2002.
35. McClure WR, Cech CL. On the mechanism of rifampicin inhibition of RNA synthesis. J Biol Chem 1978;253:8949-56.
36. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
37. Cole ST. Rifamycin resistance in mycobacteria. Res Microbiol 1996;147:48-52.
38. Musser JM. Antimicrobial agent resistance in mycobacteria: Molecular genetic insights. Clin Microbiol Rev 1995;8:496-514.
39. Torres MJ, Criado A, Palomares JC, Aznar J. Detection of rpoB mutations in Mycobacterium tuberculosis with LightCycler technology. J Clin Microbiol 2002;40:735.
40. March F, Garriga X, Rodríguez P, Moreno C, Garrigo M, Coll P, et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 1997;25:1044-7.
41. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000;6:1043-7.
42. Zierski M, Bek E. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle 1980;61:41-9.
43. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-7.
44. Raynaud C, Laneelle MA, Senaratne RH, Draper P, Laneelle G, Daffe M. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999;145:1359-67.
45. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997;3:567-70.
46. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996;93:11919-24.
47. Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, Jacobs WR Jr, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997;41:1677-81.
48. Alcaide F, Pfyffer GE, Telenti A. Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob Agents Chemother 1997;41:2270-3.
49. Inderlied C, Salfinger M. Antimycobacterial agents and susceptibility tests. En: Murray P, Baron E, Pfaller M, Tenover F, Yolken R, editors. Manual of clinical microbiology. 7 ed. Washington: ASM Press, 1999. p. 1601-23.
50. Meier A, Sander P, Schaper KJ, Scholz M, Bottger EC. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2452-4.
51. Davidson PT. Treatment of mycobacterial infections. Bull Int Union Tuberc Lung Dis 1988;63:23-5.
52. David HL. Resistance to D-cycloserine in the tubercle bacilli: Mutation rate and transport of alanine in parental cells and drug-resistant mutants. Appl Microbiol 1971;21:888-92.
53. McClatchy JK, Kanes W, Davidson PT, Moulding TS. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 1977;58:29-34.
54. Wallace J. Antimycobacterial agents. En: Mandell G, editor. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2000; p. 436-48.
55. Dukes CS, Sugarman J, Cegielski JP, Lallinger GJ, Mwakyusa DH. Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania. Trop Geogr Med 1992;44:308-11.
56. Nunn P, Porter J, Winstanley P. Thiacetazone-avoid like poison or use with care? Trans R Soc Trop Med Hyg 1993;87:578-82.
57. O'Brien RJ, Lyle MA, Snider DE Jr. Rifabutin (ansamycin LM 427): A new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987;9:519-30.
58. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996;40:2655-7.
59. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996;40:1053-6.
60. Centers for Disease Control and Prevention. Impact ofHIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. Morb Mortal Wkly Rep 1996;45:921-5.
61. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-80.
62. Kocagoz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996;40:1768-74.
63. Takiff HE, Cimino M, Musso MC, Weisbrod T, Martínez R, Delgado MB, et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996;93:362-6.
64. Cambau E, Jarlier V. Resistance to quinolones in mycobacteria. Res Microbiol 1996;147:52-9.
65. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997;25:1213-21.
66. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1341-4.
67. Klemens SP, Sharpe CA, Rogge MC, Cynamon MH. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994;38:1476-9.
68. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999;43:3001-4.
69. Tomioka H. Prospects for development of new antimycobacterial drugs. J Infect Chemother 2000;6:8-20.
70. Andriole V. Quinolones. New York: Churchill Livingstone, 1990.
71. Eustice DC, Feldman PA, Zajac I, Slee AM. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988;32:1218-22.
72. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997;41:2127-31.
73. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999;43:1189-91.
74. Valencia ME, Moreno V, Laguna F, González-Lahoz JM. Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities? Enferm Infecc Microbiol Clin 2001;19:37-9.
75. Amsden G. Tables of antimicrobial agent pharmacology. En: Mandell G, editor. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2000; p. 551-601.